Jing-Wei Li - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Jing-Wei Li

Showing results (81-90 of 83) with videos related to

Pageof 9

Sort By:

You have reached the last page of results.This site can display upto 83 results.

Diabetes, Obesity & Metabolism|March 26, 2021

The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trialClare Arnott, Jing-Wei Li, Christopher P Cannon, et al.

Journal of the American Heart Association|August 5, 2022

Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE TrialJing-Wei Li, Clare Arnott, Hiddo J L Heerspink, et al.

Clinical Journal of the American Society of Nephrology : CJASN|February 23, 2021

Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary AnalysisMeg Jardine, Zien Zhou, Hiddo J Lambers Heerspink, et al.

Pageof 9

Search research articles

Showing results (81-90 of 83) with videos related to

Sort By:

Pageof 9

You have reached the last page of results.This site can display upto 83 results.

Diabetes, Obesity & Metabolism|March 26, 2021

The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trialClare Arnott, Jing-Wei Li, Christopher P Cannon, et al.

Journal of the American Heart Association|August 5, 2022

Clinical Journal of the American Society of Nephrology : CJASN|February 23, 2021

Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary AnalysisMeg Jardine, Zien Zhou, Hiddo J Lambers Heerspink, et al.

Pageof 9